eShowcase: QUMAS Compliance Closed-Loop Process
System treats compliance as a single, repeatable process to ensure organizational quality
System treats compliance as a single, repeatable process to ensure organizational quality
QUMAS (Florham Park, NJ) has released an end-to-end closed-loop compliance solution for life science companies. The QUMAS Compliance Closed-Loop Process™, which the company says is the first product of its kind in the industry, automates the tracking and management of compliance, business, and quality issues enterprise-wide.
The solution integrates various tasks with other processes critical to regulatory compliance. Rather than treating compliance as a series of silos that vary with department and/or product lifecycle stage, the Compliance Closed-Loop Process treats it as a single procedure.
The QUMAS approach automates the generation of internal or external complaints, product nonconformances, deviations, audits, investigations, and all other compliance actions. The tool captures, records, routes, and verifies completion and approvals while auditing each step in a sponsor's quality management process.
QUMAS, (800) 577-1545, www.qumas.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
